Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Direct Reprogramming for Predictive Nephrotoxicity Testing (DRiPNeT).

Project description

Human-first approach to safer drug testing

Acute tubular necrosis is a major cause of drug failure. However, current animal and cell models do not really act like human kidneys. In this context, the ERC-funded DRiPNeT project aims to address this issue. It will use directly reprogrammed renal epithelial cells (iRECs) to build a human-specific platform capable of high-throughput nephrotoxicity testing. This iREC system works faster, produces consistent results, and is more like a real kidney than current models. The project will validate the platform and assess its market potential. The goal of the DRiPNeT method, which uses human cells, is to reduce drug failures, protect patients, and accelerate the availability of safer treatments.

Objective

Acute tubular necrosis (ATN) is a major cause of nephrotoxicity-related drug attrition in clinical trials, yet current preclinical models rely on animal studies or immortalized renal cell lines, which lack human physiological relevance. To address this gap, we have developed a directly reprogrammed renal epithelial cell (iREC) platform, enabling a human-specific, scalable, and high-throughput nephrotoxicity screening assay.
Our iREC-based system overcomes the limitations of primary, or iPSC-derived models by offering a rapid, reproducible, and physiologically relevant alternative model. Building on the advances of the ERC-Starting Grant project DiRECT, this project will validate the iREC-based platform by screening a curated panel of nephrotoxic and non-nephrotoxic compounds, assessing performance metrics, such as specificity, sensitivity, and Predictive value to benchmark against other model systems.
This project aims to establish the technical and commercial feasibility of iREC-based nephrotoxicity testing, seeking more predictive human-based preclinical models. The outcome will provide a cost-effective, scalable alternative to animal testing renal safety screen. Ultimately, this project will help reduce late-stage drug failures, improve patient safety, advance personalized risk prediction, and accelerate the development of safer therapeutics.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

UNIVERSITAT ZURICH
Net EU contribution
€ 150 000,00
Address
RAMISTRASSE 71
8006 Zurich
Switzerland
Region
Schweiz/Suisse/Svizzera Zürich Zürich
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)